Glatiramer acetate (GA) is approved for the treatment of multiple sclerosis (MS). However, the mechanism of action of GA in MS is still unclear. In particular, it is not known whether GA can modulate the pro-inflammatory Th17-type immune response in MS.
View Article and Find Full Text PDFZh Nevrol Psikhiatr Im S S Korsakova
April 2019
This article presents two clinical cases of patients diagnosed with Balo's concentric sclerosis. Distinctive features of the pathogenesis in the aspect of differential diagnosis from other forms of multiple sclerosis and possible treatment are discussed.
View Article and Find Full Text PDFZh Nevrol Psikhiatr Im S S Korsakova
November 2018
Unlabelled: The article presents the results of international multicenter randomized double-blind, active and placebo-controlled, comparative phase 3 trial. The goal of the study was to demonstrate non-inferiority of BCD-063 (glatiramer acetate, manufactured by JSC «BIOCAD», Russia) to copaxone-Teva (Teva Pharmaceutical Enterprise Co., Ltd.
View Article and Find Full Text PDFZh Nevrol Psikhiatr Im S S Korsakova
January 2014
Multiple sclerosis is now regarded as a disease, which is based on genetic predisposition. Trigger mechanism are various exogenous factors. The Epstein-Barr virus is thought to be a trigger.
View Article and Find Full Text PDFThe mechanisms triggering most of autoimmune diseases are still obscure. Autoreactive B cells play a crucial role in the development of such pathologies and, in particular, production of autoantibodies of different specificities. The combination of deep-sequencing technology with functional studies of antibodies selected from highly representative immunoglobulin combinatorial libraries may provide unique information on specific features in the repertoires of autoreactive B cells.
View Article and Find Full Text PDF